Actively Recruiting
Open-Label Extension Trial to Evaluate the Safety and Tolerability of Oral TEV-56286 in Adults with Multiple System Atrophy
Led by Teva Branded Pharmaceutical Products R&D LLC · Updated on 2026-10-09
200
Participants Needed
41
Research Sites
2 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the long-term safety and tolerability of TEV-56286, an oral drug, for adults with Multiple System Atrophy MSA. This Phase 2 trial aims to observe how well participants tolerate the medication over an extended period and to further describe its safety profile. The study is sponsored by Teva Branded Pharmaceutical Products R&D LLC and plans to include participants aged 30 and older. Participants in the trial will receive TEV-56286 orally throughout the study. This open-label extension trial follows up on a previous double-blind trial, focusing on continued treatment and monitoring. The total planned duration for participant involvement is approximately 100 weeks, allowing for long-term observation of safety and tolerability. During the study, participants will undergo regular assessments to monitor adverse events, vital signs, laboratory test results including hematology and chemistry, and 12-lead ECG measurements. Researchers will track any side effects and reasons for withdrawal throughout the 100-week period. The trial includes safety follow-up visits and aims to collect comprehensive data on the long-term effects of TEV-56286 in adults with MSA.
CONDITIONS
Brief Title
An Extension Trial to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy
Research Team
T
Teva U.S. Medical Information
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here